Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.94M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
112M
-
Shares change
-
-159K
-
Total reported value, excl. options
-
$123M
-
Value change
-
-$3.79M
-
Put/Call ratio
-
1.69
-
Number of buys
-
36
-
Number of sells
-
-39
-
Price
-
$1.09
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q3 2023
111 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q3 2023.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 112M shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (16M shares), NEA Management Company, LLC (15M shares), BlackRock Inc. (8.16M shares), VANGUARD GROUP INC (7.82M shares), Polar Capital Holdings Plc (7.5M shares), ORBIMED ADVISORS LLC (7.13M shares), Tri Locum Partners LP (6.25M shares), Stonepine Capital Management, LLC (5.27M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (4.28M shares), and MILLENNIUM MANAGEMENT LLC (3.62M shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.